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PERSPECTIVE
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Abstract
Alzheimer’s disease (AD) is a continuum consisting of a preclinical stage that occurs
decades before symptoms appear. As researchers make advances in investigating the
continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention
it is important to define what are the earliest biological stages of AD. The Alzheimer’s
Association Research Roundtable convened November 27 to 28, 2018 to focus on preclinical AD. This review will address the biological approach to defining pre-clinical AD,
detection, identification of at-risk individuals, and lessons learned from trials such as
A4 and TOMMORROW.
KEYWORDS

clinical trials, Alzheimer’s disease, biomarkers, research roundtable

INTRODUCTION

article focuses on strategies to address AD, acknowledging that “pure”
AD (amyloid and tau pathology in isolation) is uncommon and that

More than 50 million people worldwide are living with dementia,

AD more routinely exists in the presence of other misfolded proteins

with Alzheimer’s disease (AD) being the most frequent etiology. This

(eg, alpha synuclein, TAR DNA-binding protein 43 or TDP-43) and/or

number is expected to exceed 130 million by 2050 if nothing is done

vascular disease.2 Despite tens of billions of dollars invested by var-

developing.1 This

ious organizations over the past 20 plus years, no therapies have yet

to slow or prevent the spectrum of dementia from
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emerged that have slowed the clinical course of AD. At the same time,

reasons, the Alzheimer’s Association Research Roundtable focused its

significant progress has been achieved in our understanding of AD

Fall 2018 meeting on preclinical AD, providing a forum for experts

pathophysiology and on the development of soluble and imaging (and,

from academia, industry, and regulatory agencies to discuss the current

more recently, digital) biomarkers that enable diagnosis even before

understanding of preclinical AD and the opportunities and challenges

there is any clinical symptomatology. The implications for the field are

that must be overcome to translate that understanding into effective

enormous. Most important is that an understanding of the course of the

strategies for preventing dementia.

disease at such an early time point will allow for the testing of potential
therapeutic modalities before there is significant pathology and at a
time when therapeutic intervention may have its greatest impact.

2

DEFINING PRECLINICAL AD

Delaying the onset of AD has the potential not only to improve
the quality of life, lessen disability, and support independent living

According to the National Institute on Aging/Alzheimer’s Association

for millions of people worldwide, but also to reduce the tremendous

Research Framework, which defines AD biologically rather than clin-

global economic impact of the disease. Preventing AD, however, can

ically, preclinical AD may be defined through the use of biomark-

be accomplished only if the disease can be identified and treated

ers. In this conceptualization, biomarkers are grouped according to

before neurodegeneration has resulted in pathologies sufficient for the

the neuropathologic process measured: A for amyloid, T for tau, and

appearance of clinical symptomatology. Preclinical AD is the term used

(N) for neurodegeneration/neuronal injury. The (N) biomarker group

to describe the disease state in people who have pathological evidence

is placed in parentheses to indicate that although useful for staging,

of the AD process but no clinical signs and symptoms. A recent multi-

these measures are not specific for AD and thus are not diagnostic

state model used to forecast the prevalence of preclinical and clinical

biomarkers. The AT(N) classification system is rooted in the hypothet-

AD estimated that in 2017, a total of 46.7 million Americans had pre-

ical biomarker curves proposed by Jack et al. in 20106 and updated

clinical AD compared with ≈3.65 million with clinical (mild-severe AD

in 20137 (Figure 1), which have been generally supported by addi-

spectrum) AD and 2.43 million with mild cognitive impairment (MCI).3

tional clinical pathological data from prospective studies in autosomal

By 2060, the number of people with preclinical AD is expected to rise

dominant autosomal dominant AD (ADAD),8 sporadic AD, and aging

to about 75 million in the United States. According to this model, pre-

cohorts.7 These data support the hypothesis that cerebral amyloid

clinical AD affects 38% of the U.S. population over the age of 50. Glob-

beta (Aβ) pathology can be detected in the cerebrospinal fluid (CSF)

ally, these numbers are much higher. Many people with preclinical AD,

as reduced concentration of aggregation-prone Aβ42 protein, and as

however, may not go on to develop AD dementia because of competing

aggregates in the brain by positron emission tomography (PET), 15 to

morbidities and other factors that are not well understood.4

However,

25 years before clinical symptoms appear.9,10 Furthermore, these data

with improving strategies for detection and greater longevity, the num-

indicate that tau is detectable in the CSF about 10 to 15 years before

ber of people who progress may actually increase.

the onset of symptoms,9,11 and closer to symptom onset by tau PET.12

Accurate identification of preclinical AD may allow successful ther-

It is this period in the disease continuum that is considered preclini-

apies to delay or prevent the onset of clinical and functional symp-

cal, when there is only biomarker-based evidence of pathology with no

tomatology that results in a diagnosis of dementia. Yet given the poten-

obvious cognitive clinical symptoms.13,14

tial high cost of AD drugs in development, the cost of providing those

The Research Framework is flexible with regard to the addition

drugs to all patients with preclinical AD would likely lead to a massive

of other putative and validated disease biomarkers, as they become

increase in total prescription costs, as well as for costs for detection

available; for example, markers of decline in glucose metabolism mea-

and infusion therapy. These costs theoretically would be offset over

sured with fluorodeoxyglucose PET (FDG-PET),8-10 hippocampal atro-

time by a reduction in the amount spent caring for people with AD

phy or cortical thinning assessed with magnetic resonance imag-

dementia, which in 2010 was estimated to total about $200 billion in

ing (MRI),15 microglial activation assessed by CSF-soluble triggering

the United States alone.5

receptor expressed on myeloid cells-2 (TREM2) level,16 or neuronal

Moreover, the shift in paradigm from treating people with clinical

injury markers such as neurofilament light.17-19 These biomarkers may,

disease to those with preclinical disease presents challenges for drug

with further validation, also be used to identify preclinical populations

developers, regulators, clinicians, and health systems, as well as ethi-

for secondary prevention studies.

cal challenges and concerns about the potential for overdiagnosis and

The operationalization of the National Institute on Aging and

obligatory treatment that may extend out for decades, resulting in

Alzheimer’s Association (NIA-AA) staging scheme was also evaluated

explosive prescription costs. Because only some proportion of individ-

from a clinical perspective. This led the committee to create a numer-

uals who have the pathologic (biomarker) signature of AD will progress

ical staging scheme for individuals in the AD continuum. According to

to demonstrate memory impairment, and only a subset of those will

this staging system, Stages 1 and 2 represent preclinical AD. In a 2018

continue to progress to the point where the memory/cognitive impair-

guidance on early AD, the U.S. Food and Drug Administration (FDA)

ments progress to the point of impairing function (“dementia” diag-

also recognized six stages, with Stage 2 akin to early MCI, thus provid-

nosis), there must be a clear benefit-risk profile for the treatment of

ing a regulatory pathway to drug approval using this staging scheme.20

biomarker-positive, clinically asymptomatic individuals at the greatest

The Mayo Clinic Study of Aging was used as a platform to discuss

risk for developing dementia over very extended periods. For all these

the implementation of a variety of clinical measures to characterize
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F I G U R E 1 Dynamic biomarker model: modified amyloid cascade. Time-shifted curves representing the biomarkers temporal manner of
pathophysiologic processes incorporating the ATN classification framework with (A) for amyloid, T for tau, (N) for neurodegeneration or neuronal
injury, and additional (C) for cognitive clinical symptoms. The horizontal axis represents time and the vertical axis represents biomarker severity
(abnormality) from normal (min) to abnormal (max) with the black horizontal line denoting the detection threshold.

the stages. Operationalizing Stage 2 was particularly challenging, with

their estimated age at disease onset. The Alzheimer’s Prevention

measures proposed to characterize the objective and subjective cog-

Initiative (API) is also conducting a study in individuals with ADAD.

nitive dimensions as well as neurobehavioral symptoms. Among these

The API-ADAD trial will enroll asymptomatic PSEN1 E280A mutation

three defining characteristics, a change in cognition was the most fre-

carriers from family kindred with ADAD in Colombia.23 DIAN-TU is

quently used measure to characterize people in Stage 2. When the

also planning a Primary Prevention study that will enroll participants

stages were assessed for stability longitudinally, Stage 2 appeared to

18 years and older who are without evidence of Aβ-PET pathology. The

be the most labile. That is, over 40 percent of the persons originally

development of the DIAN-TU platform trial will allow for enrollment

classified as Stage 2 reverted to Stage 1 when re-evaluated 15 months

of multiple intervention arms simultaneously and consecutively and

after the initial assessment. However, in the presence of greater amy-

the sharing of placebo data between different interventions in order

loid levels, fewer individuals reverted to Stage 1. Caution is needed to

to maximize trial efficiency and power.24

interpret these results, however, due to the many variables that come
into play with regard to operationalizing the various stages. Additional
research on longitudinal clinical progression is needed. Nevertheless,

3.1

The challenge of detecting preclinical AD

the staging scheme appears to be useful for delineating individuals
along the cognitive continuum of persons who were amyloid positive,

Imaging and fluid biomarkers may be useful in detecting preclinical AD.

and this proposed scheme may be useful to further define individuals

Blood-based biomarkers offer substantial advantages for screening

who would be eligible for randomized controlled trials in preclinical AD.

large populations due to their reduced invasiveness, lower costs,
and increased acceptance by patients, but improving sensitivity and
reliability is key to recognizing these advantages.25 Several large inter-

3
GATHERING EVIDENCE TO SUPPORT
TREATING AD AT THE PRECLINICAL STAGE

national consortia have been established to advance the development
of blood-based biomarkers.26-29 Cognitive changes, sleep quality, and
behavior may also offer opportunities to detect preclinical AD, as

Secondary prevention trials for AD are those that target individuals

discussed below.

who are clinically normal but have pathological signs indicating that
the disease process is underway; that is, those with preclinical AD.21
The Anti-Amyloid Treatment in Asymptomatic AD (A4) Trial is an

3.1.1

Biomarkers of preclinical AD

example of a secondary prevention trial because it is enrolling people
with evidence of elevated brain amyloid.22 Other relevant trials

Imaging biomarkers that may be helpful in identifying preclinical AD

currently underway include primary prevention studies in high-risk

in individuals who are cognitively unimpaired include amyloid and

participants who have not yet manifested pathological signs of AD;

tau aggregation load as determined using PET, and neurodegenera-

The Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU)

tion and neuronal injury as measured by structural magnetic reso-

is enrolling young, cognitively healthy individuals with autosomal dom-

nance imaging (MRI) and glucose hypometabolism as measured by

inant highly penetrant mutations that cause autosomal dominant AD

FDG-PET. Three amyloid PET ligands—florbetapir, florbetaben, and

(ADAD) with almost 100% certainty and who are up to 15 years before

flutemetamol)—are currently approved, and a new ligand, fluselenamyl,
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is in development.30-33 The three approved agents are specific for Aβ

NFL has also shown promise as a plasma biomarker of neurodegen-

plaques or Aβ in the vessel walls, and images produced from PET scans

eration for AD. Several studies have shown that plasma NFL correlates

with all three ligands correlate with autopsy findings. However, known

with CSF NFL and neuroimaging markers as an indicator of neurode-

limits to the sensitivity of each agent mean that a negative scan does

generation across the AD continuum, is higher in people with both MCI
and AD, even after correcting for age,48 and is associated with cog-

not prove the absence of Aβ deposits in all cases.
Several tau radioligands are currently being evaluated in clinical

nitive decline and neuroimaging biomarkers of AD.18,19,49 Serum NFL

research studies. The most well studied at this point is flortaucipir

concentration increases 5 to 15 years prior to clinical disease onset in

(18F-AV-1451), which binds specifically to 3R and 4R tau (the isoforms

familial AD and may thus be an easily accessible biomarker for onset of

that make up the paired helical filaments in the AD brain), generally fol-

neurodegeneration.19

lows the topographic distribution of neurofibrillary tangles described

Other plasma biomarkers have also shown some promise. Blood

in typical AD by Braak et al., and produces images that show binding in

amyloid biomarkers results have been somewhat inconsistent in the

areas of the brain where neurodegeneration is associated with cogni-

literature50,51 ; however, plasma Aβ42/40 ratio measured by mass spec-

tive

impairment.34

It is currently under review by the FDA. As is the

trometry has been shown to provide a sensitive and reliable measure

case with amyloid PET, tau PET has sensitivity limitations as well as

of amyloid status that predicts future progression to positive amyloid

off-target binding, which may compromise diagnostic accuracy.35

Mea-

PET and correlates with CSF Aβ42/40.51-52 Plasma T-tau is elevated in

sures of neurodegeneration, atrophy, and hypometabolism reflect loss

persons with AD as well as other brain disorders,53-55 and plasma P-

(MRI) or dysfunction (FDG-PET) of dendritic spines, synapses, and neu-

tau has been shown to be a sensitive and specific predictor of elevated

rons, but neither measure is specific for AD; however, their prognostic

brain Aβ, which suggests it may be useful for screening,56 although

value increases when combined with biomarkers of amyloid and tau.

more research is needed on the topic.

CSF biomarkers may also be used as markers of A, T, and (N).

Plasma is also being tested with explorative mass spectrometry

CSF Aβ42 is well accepted as a marker of the pathophysiologic state

approaches to identify changes in the proteome that reflect differ-

associated with development of senile plaque pathology.36 Low levels

ent disease states.57 The Accelerating Medicines Partnership for AD

with a concordance of ≈90%,

(AMP-AD) has undertaken a multi-institute, large-scale proteomics

which increases as the disease progresses.39 CSF Aβ42 declines to its

approach to profile proteomic changes across the AD continuum.

minimum level at least 5 to 10 years before dementia develops, indicat-

Designed to provide a deeper understanding of the molecular mech-

ing its usefulness as a preclinical marker40-41 ; however, it is less useful

anisms underlying disease progression, these studies may also identify

at the symptomatic stage and may have greater limits as an outcome

biomarkers that can be used in clinical trials and clinically.

correlate well with amyloid

PET37-38

measure in preclinical AD trials. CSF Aβ42 may also be reduced in

Roundtable participants stressed the need to be realistic about the

the presence of neuroinflammation, normal pressure hydrocephalus,

utility of blood biomarkers. They may be ideal for large-scale screen-

and other disease states; and there may also be constitutively low Aβ

ing in primary care clinics where they can reach broad populations to

producers who are close to the Aβ42 cut point for positivity. Fortu-

rule out Aβ positivity. However, for other contexts of use, such as a

nately, using the ratio of CSF Aβ42/Aβ40 corrects for this problem and

biomarker of progression, more research is needed. The infrastructure

provides an accurate biomarker for early AD,42 which is easy to inter-

is in place to validate several screening markers; however, it will be nec-

pret, has a robust correlation to pathology, becomes clearly abnormal,

essary to identify and quantify sources of variability.

and does not change over time in symptomatic disease. Moreover,
in recent years, fully automated assays with low variation have
become available, along with standardized reference methods and
materials.

3.1.2
Psychometric approaches to detecting
preclinical AD

CSF tau is more complicated. CSF total tau (T-tau) and phosphorylated tau (P-tau) are strongly associated with AD.43 A recent study of

By definition, cognition remains in norm.al limits in older adults classi-

the relationship between CSF T-tau and P-tau and tau PET using the

fied with preclinical AD. Despite the absence of abnormality, multiple

ligand flortaucipir (18F-AV-1451) showed that CSF P-tau and T-tau are

longitudinal studies have shown that in cognitively normal individuals,

elevated in preclinical AD and may appear even before the deposition

positive Aβ biomarkers are associated with increased risk of progres-

of tau.44

The lack of correlation with tau-PET and post-mortem pathol-

sion to MCI and dementia.58-61 Furthermore, even before clinical dis-

ogy suggests that CSF tau may reflect a disturbance in disease home-

ease progression, serial neuropsychological assessments show positive

ostasis rather than the pathologic burden of tau deposits.

Aβ biomarkers to be associated with subtle (i.e., Cohen’s d = ∼0.5) but

Neurofilament light (NFL) protein is a component of the neural
cytoskeleton. Its presence in the CSF reflects damage or degeneration

relentless decline in cognition when compared to change in matched
Aβ-negative controls.

of neurons.45 Elevated levels of CSF NFL are seen in many neurodegen-

In preclinical AD, amyloid-related cognitive decline is most evident

erative diseases including AD,46 where CSF NFL concentrations begin

in episodic memory, although there is also evidence for decline in other

to increase in the early stages of disease and continue to increase over

domains, including attention, language, and visuospatial function and

time.47 High levels are associated with disease progression, more pro-

when such measures of cognition are combined into constructs such

nounced cognitive decline, and faster brain atrophy.

as global cognitive function.62 Strong associations between cognitive
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decline and the presence of abnormal biomarkers makes cognitive out-

than a psychiatric comparator group consisting of late-life psychiatric

come measures optimal end points for clinical trials of drugs designed

disorders,78 highlighting the distinction between MBI and psychiatric

to forestall the development of AD. The Preclinical Alzheimer’s Cog-

disorders.72 Thus, detecting early the NPS that constitute MBI may aid

nitive Composite (PACC) is a global outcome measure developed

in earlier detection of dementia at the preclinical or prodromal phase,

in accordance with recommendations from the FDA that cognitive

in advance of or in addition to cognitive impairment.

changes used to assess drug effects in preclinical AD reflect perfor-

Further exploration of MBI prognostication for incident cognitive

mance across multiple aspects of cognition as well as considering the

decline and dementia is part of the research agenda in this field,79

importance of memory decline in the disease. PACC scores and similar

but early results suggest that MBI may be an easily implemented

cognitive composites are being used currently as cognitive end points

approach to capture an enriched biomarker-positive group of older

in the A4 and Generation studies. PACC scores can be derived from the

adults with normal cognition, providing a chance for earlier interven-

neuropsychological batteries used in many of the large natural history

tion and enrollment in prevention trials.79 Thus, screening for emer-

studies, and in each case such scores have been shown to adequately

gent neuropsychiatric symptoms may provide a simple and efficient

capture progression of disease throughout the preclinical stages.63

method to identify a high-risk population for dementia.

3.1.3
Subjective cognitive decline and mild
behavioral impairment in preclinical AD

3.1.4

Sleep quality and preclinical AD

Poor sleep is associated with decreased cognitive performance in older
Subjective cognitive decline (SCD) is associated with an increased risk

adults,80,81 and excessive daytime sleepiness (EDS) was shown to be

of progression to MCI and dementia and may be one of the first cog-

predictive of cognitive decline in the French Three City Study.82 More-

nitive symptoms of AD, associated with biomarker

positivity.64

SCD is

over, in the Baltimore Longitudinal Study of Aging, EDS was associated

detectable in preclinical AD using self- and informant-reported sub-

with amyloid positivity.83 Short sleep duration (<6 hours per night) is

jective memory questionnaires and neuropsychological assessments,

associated with greater amyloid burden84 ; and prolonged sleep dura-

including tools such as the PACC, ECog, Blessed memory test, and Cog-

tion (>9 hours per night) has been shown to be associated with an

nitive Change Index (CCI).65-67 SCD-plus criteria include complaints of

increased risk of dementia,85 further indicating that disrupted sleep

memory impairment over other domains, onset of cognitive complaints

may be an early marker of neurodegeneration.

within the last 5 years or over the age of 60, concerns over cognitive

In preclinical AD, individuals with the lowest sleep efficiency com-

decline worse than others of a similar age, confirmation of cognitive

pared to those with the best sleep efficiency were 5 times more likely to

decline by an informant, and apolipoprotein E gene (APOE) ε4 carriage;

have elevated Aβ.86 Aβ pathology has also been associated with longer

How-

sleep latency.87 Among those at risk for AD, worse subjective sleep

ever, SCD may also be associated with psychiatric symptoms includ-

quality, increased sleep problems, and EDS were shown to be asso-

ing depression and anxiety, the presence of which may confound the

ciated with increased Aβ and tau86,87 ; and baseline EDS was associ-

assessment of SCD.66

ated with increased Aβ accumulation in the nondemented elderly, sug-

and increase the likelihood that SCD reflects preclinical

AD.68

Changes in behavior and personality, better framed as neuropsychi-

gesting that the presence of EDS indicates increased vulnerability to

atric symptoms (NPS), are included in the diagnostic criteria for demen-

pathological changes associated with AD.88 Because the association

tia, including dementia of the Alzheimer’s type, frontotemporal demen-

between sleep and AD appears to be bidirectional, treating late-life

tia (FTD), and vascular dementia.69 Evidence suggests, however, that

sleep disturbance may help prevent or slow the development of AD.

NPS emerge frequently in advance of cognitive impairment. A recent
analysis of National Alzheimer’s Coordinating Center data demonstrated that of those participants who developed AD, 30% developed

3.1.5

Polygenic risk prediction of preclinical AD

NPS in advance of MCI.70 Patients who develop dementia are often
given psychiatric diagnoses for what are early manifestations of neu-

Genetic data obtained in genome-wide association studies (GWAS) by

rodegenerative disease71-73 ; thus better awareness of NPS as potential

the International Genomics of Alzheimer’s Project (IGAP) has been

markers of incident cognitive decline and dementia is required.

used to calculate polygenic risk scores (PRS) that predict AD with a high

Mild behavioral impairment (MBI) is a validated syndrome that char-

degree of accuracy.89 PRS can be used to identify candidates for trials

acterizes these later-life acquired and sustained NPS and frames them

and may, with further validation, be useful to inform treatment deci-

as an at-risk state for incident cognitive decline and dementia. For

sions and help patients and families plan for the future. A caveat in the

some preclinical individuals, MBI is the index manifestation of neurode-

use of PRS is that they are applicable only to the population from which

generation, observed in advance of cognitive

impairment.73-75

MBI is

associated with faster cognitive decline in a large community popula-

they were derived, which currently means people of European descent.
They also should be used in combination with other disease indices.

tion with normal cognition76 and has shown to significantly increase

Similar to PRS, polygenic hazard scores (PHSs) predict absolute

the progression rate to dementia in those with normal cognition or

age-related risk, which may be more useful in identifying people in

MCI.77 MBI has demonstrated a higher conversion rate to dementia

the preclinical stage of disease. Desikan et al. developed a PHS that

6 of 9

MCDADE ET AL .

retrospectively predicted age of onset and rate of progression to

idated for online administration. This test used longitudinally allows

AD in asymptomatic older adults and showed that it correlates with

BHR to identify individuals with declining cognition who may be eligible

biomarker and neuropathology measures.90 They went on to show

and appropriate for prevention trials, and then refer willing individuals

that the PHS could be used prospectively to predict rate of progression

to trial sites.

to AD in individuals with both preclinical AD and MCI, and that the
PHS was more strongly predictive compared to APOE status alone.91
In addition, they showed that the combination of PHS and biomarkers
status predicted accelerated clinical

progression.92

PHS may thus be

3.2
Ethical and regulatory aspects of developing
treatments for preclinical AD

useful both to enrich preclinical AD trials with biomarker-positive
Both the European Medicines Agency (EMA) and FDA have published

individuals and as a stratification marker in clinical trials.

guidelines for testing compounds in early AD,100,101 and both of these
guidelines rely heavily on biomarkers, applied in various contexts of

3.1.6

use, which can include selecting patients, capturing disease progres-

Digital biomarkers

sion, measuring drug exposure, or demonstrating drug effects.100,101

Digital biomarkers have also attracted attention as potentially useful
in the detection of subtle cognitive and functional changes in the early

Moreover, both agencies emphasize the need for precompetitive sharing of rigorously collected standardized data across the AD scientific

stages of AD and may also be useful as sensitive secondary end points

community in order to understand disease progression and its relevant

in clinical trials. Wearable devices, smartphones, and infrared sensors

sources of variability. In Japan, drugs that target preclinical AD might

are all capable of capturing continuous high-dimensional data that

be evaluated through their “Conditional Early Approval System” that

reflect health-related aspects of daily life (eg, walking, remembering

aims to put highly useful and effective drugs into practice as quickly as

to take medication, using a computer, sleeping, and social interactions), which are inherently ecologically valid and meaningful. These
measures have not yet been widely deployed in clinical research,

possible. Early approval may rely on biomarkers as primary end points,
only if a correlation has been demonstrated between the biomarker
and a clinical effect.

and increased efforts are needed to more fully understand how best
to deploy and integrate them into trials as well as interpret and
analyze data with confidence.93-97 There is great promise that digital

3.2.1
Bioethical considerations in the translation
of preclinical AD from research into practice

biomarkers could identify those at high risk of developing clinical AD
for primary prevention and trial enrichment or be used for sensitive
secondary end points in clinical trials. The National Institutes of Health
and Veterans Administration (NIH-VA) supported CART (Collaborative
Aging Research using Technology) platform is addressing this need,
providing an open, technology-agnostic, end-to-end system for the
research community.98 In Europe, academic and industrial leaders
in the field of AD recently announced the launch of “RADAR-AD”
(Remote Assessment of Disease And Relapse—AD). The collaborative
research program aims to develop technologies that remotely identify
and measure “digital biomarkers” to assess the progression of early AD.

3.1.7

Participant registries

New criteria for defining preclinical AD are introducing ethical challenges because cognitively normal people may suddenly come face-toface with terms such as “preclinical Alzheimer’s pathological change.”
An adjunct to the A4 Study, SOKRATES (Study of Knowledge and Reactions to Amyloid Testing) is exploring the experience of learning one’s
amyloid status.102 Core aspects of this experience are concerns about
how the level of amyloid corresponds to the risk of decline, how to
interpret subtle cognitive changes, and how elevated amyloid might
affect one’s relationship with others, plans for the future, and feelings
of self-control and self-determination.

3.3
Moving forward: lessons learned from
secondary prevention trials in preclinical AD

Patient registries are critical for engaging participants in the clinical
trial process and recruiting and enrolling them in trials. For preclinical

In 2011, investigators from three academic-led prevention initiatives—

prevention AD trials, large cohorts need to be recruited, assessed, and

DIAN, A4, and API—came together to form the Collaboration for

monitored longitudinally through a variety of approaches.

Alzheimer’s Prevention (CAP). The aim of the umbrella group was to

One such registry is the Brain Health Registry (BHR), which was

harmonize efforts, avoid duplication, share data, and jointly seek regu-

established in 2014 at the University of California, San Francisco as

latory guidance. Subsequently the group was expanded to include the

an online project to recruit individuals interested in brain health and,

industry-funded TOMMORROW trial and the European Prevention

potentially, in clinical studies of AD and other brain disorders. BHR has

of Alzheimer’s Disease (EPAD). In 2016, CAP published principles to

enrolled over 60,000 participants, with the majority in their 50s and

guide data and sample sharing in preclinical AD trials.103 Sponsors and

60s, with thousands over the age of 70. More than half of those enrolled

companies involved in these trials have agreed to these principles, as

have a family history of AD. Among those age 55 and older, nearly half

have many other sponsors who are conducting large clinical trials in

have memory concerns. BHR uses a computerized test

battery99

val-

the AD space.
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Continued efforts are also needed to address constraints to data
sharing, including concerns about (1) maintaining scientific integrity of
trials, (2) not compromising the ability of a study to withstand independent scientific scrutiny, and (3) maintaining the confidentiality of trial
participants, particularly those with autosomal dominant mutations or
genetic risk factors. Functional platforms are also needed to ensure
data interoperability.
The main challenge, however, is finding drugs that effectively halt or
forestall the development of AD symptoms. Despite many disappointing trial results, there remains optimism that an effective treatment is
within reach and that prevention trials in AD will play a critical role in
identifying such effective treatments. Moreover, there is broad support
for continued efforts at lifestyle factors that decrease the burden of AD
in the population at large, a blood test to efficiently and inexpensively
detect preclinical AD and qualify biomarkers and other end points in
order to use accelerated approval mechanisms and to address other
scientific, regulatory, financial, ethical, social, organizational, and logistical challenges.
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